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The development of many new and effective drugs, and the parallel approach of a dynamic 
“treat to target” strategy, have transformed outcomes for patients with rheumatoid arthritis 
(RA). Yet despite these incredible advances, too many patients fail to achieve an adequate 
response. The current management approach is, for almost all patients, disappointingly 
uniform: try a drug and, if/when it fails to provide adequate response, try another. Drugs 
are chosen by protocol, by “gestalt”, but all too often by trial and error. The “personalised 
medicine” revolution promised decades ago, and renewed with the announcement of each 
new biomarker, has yet to make a meaningful impact on routine practice. Patients and 
clinicians are increasingly aware of the need to induce and maintain remission, prevent 
irreversible damage, minimise adverse events, and reduce cost to the individual and society. 
To achieve this, the optimal drug must be delivered to the appropriate patient at the 
earliest time. Are we any closer to finding useful predictors of treatment response in RA? 
Biomarkers for treatment response can be derived from genes (e.g., polymorphism, 
epigenetics), serum (antibodies, cytokines), tissue (cellular blood components, synovium) or 
clinical phenotype (disability, imaging). Individually or combined, it is hoped that biomarkers 
can predict who will or who will not respond. The following are some examples. A well 
performed and validated study of inadequate response to methotrexate (MTX) found high 
DAS28 (we will return to this later), smoking, and abstinence from alcohol to be good clinical 
predictors; together, their AUC (area under the receiver operating curve) was 0.75 [1]. This 
dropped to 0.67 when externally validated – not so impressive when 0.5 indicates no better 
than chance. These results are typical of the generally weak predictive ability of clinical 
factors, including sex, age and BMI [2]. Indeed, one study suggested that the combination of 
several “established” clinical predictors account for less than 17% of the variability in 
response [3]. 
From phenotype to the other end of the spectrum, genotype: These studies are often 
limited by small sample sizes and/or lack of replication/reproducibility. Of the better-known 
candidates (e.g., SLC19A1 or ATIC for methotrexate; CD84 or PDE3A–SLCO1C1 for TNF 
inhibitors) none were sufficiently predictive to inform clinical decision making [3,4]. 
Research into transcriptional or epigenetic factors (that differ from cell to cell) followed with 
much promise. However, they pose additional challenges of identifying the optimal tissue to 
study and carry much greater cost [3]. Focusing on the primary site of pathology, biomarker 
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studies using biopsies of the RA synovium have reported conflicting results [5], partly 
because of their small sample sizes. Practicalities that limit study size also limit integration 
into routine practice, even were a useful biomarker to be found. 
The only biomarker class to make its way into widespread clinical consciousness are serum 
proteins. Seropositivity for rheumatoid factor and/or anti-citrullinated protein antibodies is 
associated with rituximab response, driving some consensus statements to suggest using 
other bDMARDs in seronegative patients [6]. Elevated baseline CRP has been reported to 
predict response to TNFi and IL6 inhibitors [2]. To what extent do current biomarkers 
capture more than baseline disease activity? In a comprehensive study of tocilizumab 
response, genotypic, transcriptional and serum biomarkers of its therapeutic target, IL-6, 
failed to robustly predict response after accounting for baseline DAS28 [7]. 
Why are we no closer? Here are some important points for biomarker hunters to consider. 
Most importantly, studies must carefully define what is being predicted. Is the definition of 
response some fixed level of low disease activity (e.g., DAS28 remission), fixed degree of 
response (reduction by >1.2 units of DAS28), something borrowed from RCTs (eg American 
College of Rheumatology 70% response, ACR70), or created with real-world practice in mind 
(where the baseline disease activity matters)? Any patient group with high disease activity 
at baseline will simultaneously be: 1) more able to achieve a fixed or proportional reduction 
because there is more capacity for improvement and 2) less able to achieve a threshold for 
low disease activity because a greater absolute improvement is required. For example, high 
baseline DAS28 has been reported as a biomarker that simultaneously increase odds of 
ACR70 response and decreases odds of DAS remission [8]. Using outcomes from RCTs, 
where baseline disease activity is balanced, is inappropriate when it is not. Adjusting for 
baseline disease activity is not a robust solution when using binary outcomes [9].  
The majority of prediction studies focus on finding the optimal drug, but comparatively little 
is done on predicting non-response; ironic, when recommending against rituximab in 
seronegative patients is the nearest to personalised medicine we have got. There may be 
benefits in predicting non-response, since statistical properties are superior for common 
and more homogenous outcomes (i.e., there are fewer categorisations of non-response 
than response). However, dichotomising to response vs non-response or using percentage-
change further sacrifices statistical power that is already limited in many biomarker studies 
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[10]. Using continuous absolute change in an outcome measure, with consideration for 
baseline differences between biomarker groups, is more valid and statistically efficient. We 
may even need to question the concept of response altogether, no matter how it is 
measured, since popular trial designs make inferences about efficacy for populations not 
individuals [10]. 
Studies should consider for whom the potential biomarker will be used and for what 
purpose. Research studies often recruit from specialist academic centres with preference 
for classification criteria, while biomarkers are more likely to be applied to heterogenous 
“physician diagnosed” populations in routine practice. Even a good biomarker will fail to be 
predictive in a non-represented population. It is also unlikely that genetic or serum 
biomarkers will predict response to bDMARDs of different class equally well; even within a 
class, such as TNFi, response may not be equally predictable due to differences in 
pharmacology.  
Novel biomarker studies often report the predictive ability without comparison to existing 
predictors. The expensive biomarker may simply be a marginally better representation of, 
for example, crude markers of high disease activity or prior steroid use that are easily and 
inexpensively captured. Novel biomarker results are often not reproducible in other 
populations, partly due to inadequate analysis and/or validation. Outdated or inappropriate 
statistical methods, for example, univariate screening or stepwise variable selection remain 
prevalent [11,12]. Newer “machine learning” methods often overfit, making them 
impossible to replicate externally [13]. Many biomarkers will struggle to be implemented in 
clinical practice, due to cost or acceptability (e.g., synovial biopsies). An ideal biomarker 
candidate would be one that is already collected as part of routine practice, for example, 
the ratio of neutrophils to lymphocytes [14]. 
Despite the extensive and expensive search for biomarkers in the past decades, very little 
has changed to personalise RA treatment. This research area uniquely demands insight and 
knowledge across the spectrum of science, from genotype to phenotype and laboratory to 
epidemiological methods. Biomarkers are desperately needed, but repeating the same 
failed approach, over and over again, will unlikely get us any closer. However, far from 
recommending defeat, we challenge readers to take up this gauntlet with the conclusion 
from a recent piece on personalised medicine in Nature: “Realizing that the scope for 
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personalized medicine might be smaller than we have assumed over the past 20 years will 
help us to concentrate our resources more carefully. Ironically, this could also help us to 
achieve our goals [10].” 
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